Class Action Article

  • File A Talcum Powder Lawsuit: Talcum Powder Ovarian Cancer Lawsuits Talcum Powder Fallopian Tube Cancer Lawsuits Baby  Powder Ovarian Cancer Lawsuits Filed If you or a loved one used talcum powder products and were diagnosed with ovarian cancer, or fallopian tube can...

Class Action News

Drug Class Actions

  • Taxotere Lawyers for Permanent Hair Loss: Taxotere Baldness Lawyers For  Permanent Hair Loss Lawsuits Have you received Taxotere for breast cancer? Taxotere can result in hair loss or baldness  that is permanent. Taxotere  is a chemotherapy drug used for the treatment of breas...

Medical Device Lawsuits

  • Get A Hernia Mesh Lawyer | Hernia Mesh Lawsuits Filed: The hernia mesh lawyers of Class Action Lawyer Network are filing hernia mesh lawsuits for victims of a failed hernia mesh. We have Ethicon, Bard and Cook hernia mesh lawyers. Hernia Mesh Lawsuits Filed  For: Ethicon: Physiomesh Pro...

Posts Tagged ‘actos MDL louisiana’

I Have Heard Actos Can Cause Bladder Cancer? Is That True? How Do I File An Actos Lawsuit

Written by lisaspitzer on . Posted in Actos Lawsuit Lawyers, Drug Warnings

Actos does have warnings for bladder cancer with use for extended periods of time. Actos lawyers are filing lawsuits for people who have developed bladder cancer as a part of a multi district litigation.

FDA Warnings For Actos and Bladder Cancer

FDA Drug Safety Communication: Update to ongoing safety review of Actos (pioglitazone) and increased risk of bladder cancer

Actos Bladder Cancer Safety Announcement

[6-15-2011] The U.S. Food and Drug Administration (FDA) is informing the public that use of the diabetes medication Actos (pioglitazone) for more than one year may be associated with an increased risk of bladder cancer. Information about this risk will be added to the Warnings and Precautions section of the label for pioglitazone-containing medicines.

Actos Bladder Cancer Lawsuit

Actos lawsuits are being  filed on behalf of type II diabetics who developed bladder cancer from long-term use of the  drug Actos. These lawsuits continue to move forward in a multidistrict litigation in U.S. District Court, Western District of Louisiana. More than 2,500 Actos bladder cancer lawsuits are currently pending in the Western District of Louisiana, where the first trials are scheduled to begin in January.

Actos Product Liability Litigation, MDL No. 2299

If you believe you, a loved one or someone you are a caregiver for has gotten bladder cancer and has been on Actos call and speak to an Actos lawyer today. There must be a confirmed diagnosis of bladder cancer to be added to the lawsuit.

Actos Lawyers, Actos News, Actos Bladder Cancer Victims

Written by Class Action Lawyer on . Posted in Louisiana Multidistrict Litigation Lawyers

Actos has warnings for bladder cancer. Actos cases have been consolidated and Actos Lawyers are accepting clients.

The judge overseeing lawsuits alleging Takeda Pharmaceutical Co. (4502)’s Actos diabetes medicine causes cancer appointed 19 plaintiffs’ lawyers to manage litigation involving U.S. claims.

Takeda, Asia’s biggest drugmaker, may face as many as 10,000 claims that Actos causes bladder cancer after U.S. regulators found last year the drug was linked to the disease. Federal lawsuits against the drugmaker were consolidated before U.S. District Judge Rebecca Doherty in Lafayette, Louisiana, in December. The first hearing on the cases is set for March 22, according to court filings.

“The court has determined to effect the selection of lead counsel, liaison counsel and plaintiffs’ executive and steering committees before the March 22nd-23rd status conference,” Doherty said in a March 12 note posted on the court’s website.

The lawsuits claim patients who use Actos, a prescription drug approved to treat type 2 diabetes, face increased risks of developing bladder cancer. The plaintiffs also claim that Takeda and co-defendant Eli Lilly & Co., based in Indianapolis, withheld information about the risk and failed to provide adequate warnings.

Takeda pulled Actos, its top-selling drug, off the market in Germany and France last year after it was linked to an increased cancer risk. The medication had sales of 387.9 billion yen ($4.8 billion) last fiscal year, 27 percent of the Osaka, Japan-based company’s revenue.
Lead Counsel

“Given that litigation is pending, we can’t comment,” Jocelyn Gerst, a U.S.-based spokeswoman for Takeda, said in a telephone interview about the selection of the plaintiffs’ group.

Doherty named attorneys Richard Arsenault and Paul Pennock as lead plaintiffs’ counsel in the case and also appointed them to the executive committee, along with lawyers Mark Robinson and Hunter Shkolnik.

Arsenault, a products-liability lawyer based in Alexandria, Louisiana, served as one of the lead lawyers in consolidated cases filed against Merck & Co. (MRK) over its Vioxx painkiller that resulted in a $4.85 billion settlement in November 2007.

Pennock, a New York-based attorney, was one of the lawyers leading the consolidated suits against AstraZeneca Plc (AZN) over its Seroquel antipsychotic drug. The London-based drugmaker agreed last year to pay a total of about $350 million to resolve patients’ claims that the drug caused diabetes.
Steering Committee

The Los Angeles-based Robinson, who has won multimillion- dollar jury awards against carmakers such as Ford Motor Co., is a co-lead counsel in sudden-acceleration lawsuits against Toyota Motor Corp. (7203)

Shkolnik, based in New York City, served as a member of the plaintiffs’ steering committee in lawsuits against Medtronic Inc. (MDT) over flawed heart defibrillators. The cases later settled for more than $114 million.

Other lawyers named to the plaintiffs’ steering committee in the Actos cases include Mark Lanier, a Texas-based lawyer who won the first jury award against Whitehouse Station, New Jersey- based Merck in the Vioxx litigation, and Chris Seeger, a New Jersey-based attorney who also won a verdict against Merck on behalf of Vioxx users.

The judge also named Andy Birchfield, an Alabama-based lawyer who helped negotiate the $4.85 billion Vioxx settlement, and Vance Andrus, a Lafayette-based lawyer who was one of the lead counsels in cases against GlaxoSmithKline Plc (GS) over its Avandia diabetes drug. The London-based drugmaker has agreed to pay more than $700 million to resolve claims that Avandia caused heart attacks and strokes in users.

The lawsuits are consolidated in In Re: Actos Products Liability Litigation, 11-2299, U.S. District Court, Western District of Louisiana (Lafayette).